In a BioPharma Boardroom expert opinion, Andy Lewis (Quotient Sciences) and Christine Allen (Intrepid Labs), discuss the potential of machine learning to speed up formulation development.
The article outlines the ways that ML methods, when working collaboratively, can assist formulation and early clinical planning without replacing scientific expertise.
They discuss how Intrepid Labs proprietary machine learning (ML) platform accelerates formulation development while also generating deeper insight into the relationships between composition and performance.
Read the full article on BioPharma website.